ReviewPaediatric drugs
Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis.
Review in Paediatric drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Duration of intravenous antibiotic therapy in people with cystic fibrosis.The Cochrane database of systematic reviews · 2019Pooled it
- Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis.The Cochrane database of systematic reviews · 2015Pooled it
- Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients.Infection · 2009Trial
- Comparative efficacy of two doses of nebulized colistimethate in the eradication of Pseudomonas aeruginosa in children with cystic fibrosis.Canadian respiratory journalTrial
- Genomic variation inMicrobiology spectrum · 2025Article
- AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis.Journal of clinical microbiology · 2023Article
- Association of Biofilm Inducer withArchives of Razi Institute · 2022Article
- Duration of intravenous antibiotic therapy in people with cystic fibrosis.The Cochrane database of systematic reviews · 2016Review
- Bacterial adhesion and growth reduction by novel rubber-derived oligomers.Biochemical and biophysical research communications · 2013Article
- Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis.Pediatric pulmonology · 2012Article
- Health-related quality of life in Cystic Fibrosis patients infected with transmissible Pseudomonas aeruginosa strains: cohort study.JRSM short reports · 2012Article
- Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.Medical devices (Auckland, N.Z.) · 2011Article
- Clinical significance of microbial infection and adaptation in cystic fibrosis.Clinical microbiology reviews · 2011Review
- Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis.Radiology · 2009Article
- Clinical pseudomonas aeruginosa: potential factors of pathogenicity and resistance to antimicrobials.Folia microbiologica · 2006Article
- Hospitalisation costs of cystic fibrosis.PharmacoEconomics · 2006Article
- Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms.Antimicrobial agents and chemotherapy · 2004Article
- Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production.Antimicrobial agents and chemotherapy · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most patients with cystic fibrosis (CF) experience recurrent and chronic endobronchial Pseudomonas aeruginosa infections. It is possible to prevent or delay the onset of these chronic infections in most patients with CF by eliminating cross-infection and by early aggressive antibiotic treatment of the first positive sputum culture and of subsequent intermittent colonisation. Lung tissue damage is caused by activation of the immunologically specific inflammatory defence mechanisms of the lungs, which are initiated by the antibody response and dominated by polymorphonuclear neutrophil leucocytes and their proteolytic and oxidative products. This inflammation induces a phenotypic shift from nonmucoid to mucoid, alginate-producing phenotypes of P. aeruginosa which then grow, endobronchially, as a biofilm. Such biofilms are impossible to eradicate with antibiotics. By using chronic suppressive antibiotic maintenance therapy and anti-inflammatory drugs it is however, possible to maintain the lung function of these patients for a number of years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.